PolyPid Ltd. filings document foreign private issuer disclosures for a biopharmaceutical company developing PLEX-based controlled-release therapeutics. Form 6-K reports furnish corporate updates, financial results, FDA and NDA-related disclosures for D-PLEX100, SHIELD II clinical and pharmacokinetic information, GMP inspection updates, and business-operation summaries.
The company’s regulatory record also covers capital-structure and governance matters, including ordinary-share sales agreement disclosures, legal opinions tied to share issuance, Form F-3 and Form S-8 registration statement references, shareholder meeting results, board composition, director compensation approvals, and risk and operating disclosures incorporated into its SEC registration framework.
PolyPid Ltd. held an Extraordinary General Meeting of Shareholders on February 4, 2026, where a quorum was present and shareholders approved Proposal No. 1 as originally proposed. The specific substance of the proposal is not described in this excerpt.
The report states that this 6-K is incorporated by reference into several existing Form F-3 and Form S-8 registration statements, meaning those securities registration documents now also include this shareholder meeting outcome as part of their disclosure record.
PolyPid Ltd. received an amended Schedule 13G showing that investment manager AIGH Capital Management LLC and Orin Hirschman beneficially own 1,793,117 ordinary shares, representing 9.8% of the class. They report sole voting and dispositive power over these shares.
The filing notes that this ownership percentage excludes 2,395,268 common shares issuable upon exercise of warrants that are not currently exercisable due to beneficial ownership limits, and 549,141 shares held in abeyance. The holders state the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of PolyPid.
PolyPid Ltd. has appointed Brooke Story as a director and chairman of its Board of Directors, effective December 11, 2025. Story, age 54, is a veteran medtech executive who has led the separation and integration management office at BD since June 2024 and previously served as Worldwide President in multiple BD business units.
Before joining BD, she held senior leadership roles at Medtronic in pelvic health and gastric therapies and has board experience at LivaNova and Sigilon Therapeutics. The Board determined she is independent under Nasdaq rules. Her compensation for Board service will be presented for approval at an upcoming shareholder meeting, and she is expected to enter into PolyPid’s standard indemnification agreement for directors and executive officers.
PolyPid Ltd. filed a Form 6-K to furnish a press release dated December 3, 2025 announcing positive U.S. FDA pre-NDA meeting minutes for its D-PLEX100 product, which support a planned New Drug Application submission. The filing states that the first three paragraphs of the press release and its forward-looking statements section are incorporated by reference into several existing PolyPid shelf and equity compensation registration statements on Forms F-3 and S-8, so that those registration documents now include this updated regulatory information.
PolyPid Ltd. (PYPD) is increasing its at-the-market share offering program to a maximum aggregate offering price of up to $15,000,000 of ordinary shares under its Form F-3 shelf. This prospectus supplement raises the prior cap of $8,250,000 and continues the sales agreement with Oppenheimer & Co. Inc. as sales agent on a best efforts basis. Oppenheimer will receive a 3.0% commission on the gross sales price per share and reimbursement of up to $40,000 of specified expenses.
The company’s ordinary shares trade on Nasdaq under the symbol PYPD; the last reported sale price was $3.68 per share on November 25, 2025. The aggregate market value of ordinary shares held by non-affiliates was $65,953,832 as of October 30, 2025, based on 17,175,477 non-affiliate shares at $3.84 per share.
PolyPid Ltd. (PYPD) reports that on November 26, 2025 it increased the maximum aggregate offering price of its ordinary shares issuable under its Sales Agreement with Oppenheimer & Co. Inc. from $8,250,000 to $15,000,000. This Sales Agreement, dated November 8, 2024, allows PolyPid to issue and sell ordinary shares from time to time, typically in an at-the-market structure.
The company also filed a legal opinion from Sullivan & Worcester Tel-Aviv (Har-Even & Co.) as Exhibit 5.1, addressing the legality of issuing and selling these ordinary shares under the Sales Agreement. This report is incorporated by reference into multiple existing PolyPid shelf registration statements on Form F-3 and equity compensation registration statements on Form S-8, so that future share sales under the Sales Agreement can rely on this updated disclosure.
PolyPid Ltd. submitted a Form 6-K to furnish a press release titled “PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results.” The filing notes that the press release includes recent corporate highlights, financial results for the three and nine months ended September 30, 2025, balance sheet highlights and forward-looking statements.
These specific sections of the press release, along with the attached financial statements, are incorporated by reference into multiple existing PolyPid registration statements on Forms F-3 and S-8, so they become part of those offerings from the date of this report, unless later filings supersede them.
PolyPid Ltd. furnishes a Form 6-K to report that it has issued a press release titled “PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀.” The company also states that specific portions of this press release and its forward-looking statements section are incorporated by reference into multiple existing Form F-3 and Form S-8 registration statements, so those filings now include this new information from the date of this report.
PolyPid Ltd. disclosed that Aurum Ventures M.K.I. Ltd. and Morris Kahn each report beneficial ownership of 5,001,561 ordinary shares, representing 28.1% of the class on a fully-diluted basis that counts 1,918,879 shares issuable upon exercise of currently exercisable warrants. The filing clarifies that the reported totals do not give effect to warrant "blocker" provisions that prevent exercises that would raise beneficial ownership above 9.9% at any given time, so the actual number of shares that can be owned simultaneously is lower than the aggregate reported.
The statement explains that Mr. Kahn is the ultimate sole beneficiary of Aurum and may be deemed to share beneficial ownership of the shares held by Aurum, while disclaiming day-to-day voting or investment control over Aurum-held shares.
PolyPid Ltd. submitted a Form 6-K dated August 13, 2025, furnishing its unaudited interim condensed financial statements and management's discussion and analysis for the six months ended June 30, 2025. The filing includes XBRL-formatted financial information covering interim condensed consolidated balance sheets, statements of operations, shareholders' equity, cash flows and notes, plus an embedded Cover Page Interactive Data File. The report is submitted by the Chief Executive Officer and lists related exhibit numbers for the financial statements, MD&A and XBRL tagging.